<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03790800</url>
  </required_header>
  <id_info>
    <org_study_id>INTERACT4</org_study_id>
    <nct_id>NCT03790800</nct_id>
  </id_info>
  <brief_title>Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial</brief_title>
  <acronym>INTERACT4</acronym>
  <official_title>Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute for Global Health, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chengdu Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute for Global Health, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, ambulance-delivered, prospective, randomized, open-label, blinded endpoint&#xD;
      (PROBE) study to assess the effects of hyperacute intensive blood pressure (BP) lowering&#xD;
      initiated in ambulance setting on (i) functional outcome in patients with acute stroke (ii)&#xD;
      safety in patients with confirmed acute stroke and other conditions that were initially&#xD;
      suspected as acute stroke (i.e. stroke mimic).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As an investigator initiated and conducted, multicentre, ambulance-delivered, prospective,&#xD;
      randomised, open-label, blinded outcome (PROBE) study. INTERACT4 aims to evaluate the effects&#xD;
      of functional outcome according to an ordinal analysis of the full range of scores on the&#xD;
      mRS, the safety in all randomised patients; reperfusion treatment (thrombolysis and/or&#xD;
      thrombectomy) related symptomatic ICH (sICH, according to standard definitions), infarct&#xD;
      size, the time to and overall rate of reperfusion treatment in AIS patients; hematoma volume&#xD;
      and early expansion in ICH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>central randomization with stratification</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessor is independent of the treatment team</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>level of physical function</measure>
    <time_frame>Day 90</time_frame>
    <description>Level of function defined across 7 categories of disability on the modified Rankin scale （mRS 0-6) in which scores of 0 or 1 indicate good function without or with symptoms but not disability, socress of 2 indicates slight disability but independence, 3 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients with serious adverse events</measure>
    <time_frame>Day 90</time_frame>
    <description>total number of serious adverse events reported during follow-up, according to standard definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with any intracranial hemorrhage</measure>
    <time_frame>Day 7</time_frame>
    <description>reperfusion treatment (thrombolysis/thrombectomy) related symptomatic intracerebral number of cases of intracranial hemorrhage, according to standard definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>size of cerebral infarction</measure>
    <time_frame>Day 2</time_frame>
    <description>overall size of cerebral infarction on MRI within 2 days in cases of ischaemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients who receive reperfusion treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>total number of cases of reperfusion (thrombolysis and/or thrombectomy) in ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to use of reperfusion treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>time from symptom onset to reperfusion treatment in patients with ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with symptomatic intracerebral hemorrhage</measure>
    <time_frame>Day 7</time_frame>
    <description>number of cases of symptomatic intracerebral hemorrhage according to standard measure after reperfusion treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>size of hematoma volume</measure>
    <time_frame>Day 1</time_frame>
    <description>change in volume of hematoma from baseline to 24 hours, measured on brain imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3116</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Cerebrovascular Disorders</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If systolic blood pressure&gt;180:IV Urapidil 25mg If systolic blood pressure&gt;150 (or 5 mins after first bolus) : IV Urapidil 25mg and to maintain this level after admission to hospital in those with confirmed acute stroke for the next 7 days (or hospital discharge if earlier)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>To receive blood pressure management according to standard local guidelines which recommend blood pressure lowering in hospital if systolic level is &gt;220mmHg. This level will be considered by ambulance staff as a threshold for treatment if considered clinically important.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>urapidil</intervention_name>
    <description>A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists &gt;150 after 5 minutes.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Intensive BP lowing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age ≥18 years;&#xD;
&#xD;
          2. Acute syndrome that is due to presumed acute stroke, defined as FAST（Face, Arm,&#xD;
             Speech, Time） scores of ≥2 with an arm motor deficit and time ≤2 hours from last seen&#xD;
             well;&#xD;
&#xD;
          3. Systolic BP ≥150&#xD;
&#xD;
          4. Able to provide brief informed consent (if a waver of consent is not approved by the&#xD;
             ethics committee)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Coma - no response to tactile stimuli or verbal stimuli;&#xD;
&#xD;
          2. Severe co-morbid disease (e.g. cancer, chronic airflow disease, severe dementia,severe&#xD;
             heart failure,pre-stroke disability[needed help]);&#xD;
&#xD;
          3. History of epilepsy or seizure at onset;&#xD;
&#xD;
          4. History of recent head injury (&lt;7 days);&#xD;
&#xD;
          5. Hypoglycemia(glucose&lt;2.8mmol/L)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Anderson</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute for Global Health, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gang Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affliated Hospital of Chengdu Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lily Song</last_name>
    <phone>+86 13916466400</phone>
    <email>lsong@georgeinstitute.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The George Institute for Global Health</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Li, MD</last_name>
      <phone>86</phone>
      <phone_ext>18017187086</phone_ext>
      <email>ligang@tongji.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affliated hospital of Chengdu medical college</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610500</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Yang</last_name>
      <phone>86</phone>
      <phone_ext>13678130516</phone_ext>
      <email>yangjie1126@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 26, 2018</study_first_submitted>
  <study_first_submitted_qc>December 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2019</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The George Institute for Global Health, China</investigator_affiliation>
    <investigator_full_name>Craig Anderson</investigator_full_name>
    <investigator_title>Executive Director</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>blood pressure control</keyword>
  <keyword>hypertension</keyword>
  <keyword>clinical trial</keyword>
  <keyword>ambulances</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urapidil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared with bona fide researchers after 1 year following conclusion of the study, based on a submitted protocol to the research office of The George Institute for Global Health, Sydney Australia</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>1 year after conclusion of the study</ipd_time_frame>
    <ipd_access_criteria>genuine researcher with supporting institution protocol review and approval by the research office of The George Institute</ipd_access_criteria>
    <ipd_url>http://georgeinstitute.org.au</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

